Correspondence on ‘Development and validation of a model to predict the disease activity score: towards a remote treat-to-target approach for rheumatoid arthritis’ by Looijen et al
Annals of the Rheumatic Diseases · 2026-11 · 85 (11) · e126-e127
DOI: 10.1016/j.ard.2026.04.005 ↗Kurz gefasst
Leserbrief in der Zeitschrift Annals of the Rheumatic Diseases, 2026-11. Verfasst von Chuanfu Zhang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Seventh People's Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China. Die Arbeit nennt 5 Literaturangaben. Gefördert von: Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Seventh People's Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China. Electronic address: liangqianqian@shutcm.edu.cn.
Förderung
- Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Zhang, C., & Liang, Q. (2026). Correspondence on ‘Development and validation of a model to predict the disease activity score: towards a remote treat-to-target approach for rheumatoid arthritis’ by Looijen et al. Annals of the Rheumatic Diseases, 85(11), e126-e127. https://doi.org/10.1016/j.ard.2026.04.005
Vancouver
Zhang C, Liang Q. Correspondence on ‘Development and validation of a model to predict the disease activity score: towards a remote treat-to-target approach for rheumatoid arthritis’ by Looijen et al. Annals of the Rheumatic Diseases. 2026;85(11):e126-e127. doi:10.1016/j.ard.2026.04.005
BibTeX
@article{Zhang2026,
author = {Zhang, Chuanfu and Liang, Qianqian},
title = {Correspondence on ‘Development and validation of a model to predict the disease activity score: towards a remote treat-to-target approach for rheumatoid arthritis’ by Looijen et al},
journal = {Annals of the Rheumatic Diseases},
year = {2026},
volume = {85},
number = {11},
pages = {e126--e127},
doi = {10.1016/j.ard.2026.04.005}
}
EUVIMED